Advertisement

Pediatric Nephrology

, Volume 21, Issue 11, pp 1698–1700 | Cite as

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

  • Rodney D. Gilbert
  • Eleanor Hulse
  • Susan Rigden
Brief Report

Abstract

We present a patient with steroid-sensitive but high-dose steroid-dependent nephrotic syndrome who was treated with rituximab. For 9 months following therapy she had undetectable CD19 cells in the peripheral circulation. She remained in remission during this period even though therapy was reduced to low-dose, alternate day prednisolone only. After 9 months, CD19 cells were once again detectable. Shortly after CD19 cells became detectable again she relapsed. We conclude that B-lymphocytes play a central role in the pathogenesis of idiopathic minimal change nephrotic syndrome (MCNS) and that rituximab may have a useful role in the management of steroid-dependent patients.

Keywords

Rituximab B-lymphocytes Nephrotic syndrome Steroid sensitivity Minimal change Drug therapy 

References

  1. 1.
    Van den Berg J, Weening JJ (2004) Role of the immune system in the pathogenesis of the idiopathic nephrotic syndrome. Clin Sci 107:125–136PubMedCrossRefGoogle Scholar
  2. 2.
    Grimbert P, Audard V, Valancuite A, Pawlak A, Lang P, Guellaën G, Sahali D (2005) Abnormal RNA processing and altered expression of serine-rich proteins in minimal-change nephrotic syndrome. Pediatr Res 57:133–137PubMedCrossRefGoogle Scholar
  3. 3.
    Mansour H, Cheval L, Elalouf JM, Aude JC, Alyanakian MA, Mougenot B, Doucet A, Deschenes G (2005) T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int 67:2168–2177PubMedCrossRefGoogle Scholar
  4. 4.
    Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797PubMedCrossRefGoogle Scholar
  5. 5.
    Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663PubMedCrossRefGoogle Scholar
  6. 6.
    Meyrier A (2005) Mechanisms of disease: focal segmental glomerulosclerosis. Nature Clin Prac Nephrol 1:44–54CrossRefGoogle Scholar
  7. 7.
    Garin EH, Laflam P, Chandler L (1998) Anti-interleukin-8 antibody abolishes effects of lipoid nephrosis cytokine. Pediatr Nephrol 12:381–385PubMedCrossRefGoogle Scholar
  8. 8.
    Niemir ZI, Stein H, Ciechanowicz A, Olejniczak P, Dworacki G, Ritz E, Czekalski S, Waldherr R (2004) The in situ expression of interleukin-8 in the normal human kidney and in different morphological forms of glomerulonephritis. Am J Kidney Dis 43:983–998PubMedCrossRefGoogle Scholar
  9. 9.
    Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247PubMedGoogle Scholar
  10. 10.
    Kemper MJ, Zepf K, Klaasen I, Link A, Muller-Wiefel DE (2005) Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am J Nephrol 25:132–137PubMedCrossRefGoogle Scholar
  11. 11.
    Koskimies O, Vilska J, Rapola J, Hallman N (1982) Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57:544–548PubMedCrossRefGoogle Scholar
  12. 12.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CMJ (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMedGoogle Scholar
  13. 13.
    Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux M-F, Landais P, Lesavre P, Chaveau D, Knebelmann B, Broyer M, Grunfeld J-P, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550–557Google Scholar
  14. 14.
    Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202–207PubMedCrossRefGoogle Scholar
  15. 15.
    Hodson EM, Craig JC, Willis NS (2005) Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20:1523–1530PubMedCrossRefGoogle Scholar
  16. 16.
    Marks SD, Tullus K (2006) Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 21:598–599PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Rodney D. Gilbert
    • 1
  • Eleanor Hulse
    • 1
  • Susan Rigden
    • 2
  1. 1.Regional Paediatric Nephro-Urology UnitChild Health Department Southampton General HospitalSouthamptonUK
  2. 2.Renal UnitEvelina Children’s Hospital, St. Thomas’s HospitalLondonUK

Personalised recommendations